JPWO2022094314A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022094314A5
JPWO2022094314A5 JP2023526252A JP2023526252A JPWO2022094314A5 JP WO2022094314 A5 JPWO2022094314 A5 JP WO2022094314A5 JP 2023526252 A JP2023526252 A JP 2023526252A JP 2023526252 A JP2023526252 A JP 2023526252A JP WO2022094314 A5 JPWO2022094314 A5 JP WO2022094314A5
Authority
JP
Japan
Prior art keywords
modified
cells
cell
car
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526252A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549079A5 (https=
JP2023549079A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057407 external-priority patent/WO2022094314A1/en
Publication of JP2023549079A publication Critical patent/JP2023549079A/ja
Publication of JPWO2022094314A5 publication Critical patent/JPWO2022094314A5/ja
Publication of JP2023549079A5 publication Critical patent/JP2023549079A5/ja
Pending legal-status Critical Current

Links

JP2023526252A 2020-10-30 2021-10-29 二重標的化キメラ抗原受容体 Pending JP2023549079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108047P 2020-10-30 2020-10-30
US63/108,047 2020-10-30
PCT/US2021/057407 WO2022094314A1 (en) 2020-10-30 2021-10-29 Dual targeting chimeric antigen receptors

Publications (3)

Publication Number Publication Date
JP2023549079A JP2023549079A (ja) 2023-11-22
JPWO2022094314A5 true JPWO2022094314A5 (https=) 2024-11-07
JP2023549079A5 JP2023549079A5 (https=) 2024-11-07

Family

ID=81383292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526252A Pending JP2023549079A (ja) 2020-10-30 2021-10-29 二重標的化キメラ抗原受容体

Country Status (6)

Country Link
US (1) US20240108721A1 (https=)
EP (1) EP4237543A4 (https=)
JP (1) JP2023549079A (https=)
AU (1) AU2021368741A1 (https=)
CA (1) CA3200265A1 (https=)
WO (1) WO2022094314A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024121414A1 (en) * 2022-12-08 2024-06-13 Université De Genève Chimeric antigen receptor
WO2025252993A1 (en) * 2024-06-07 2025-12-11 Université De Genève Chimeric antigen receptor targeting glioma-associated antigens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040557A2 (en) * 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
WO2014055657A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2016123143A1 (en) * 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
US20180258149A1 (en) * 2015-09-17 2018-09-13 Novartis Ag Car t cell therapies with enhanced efficacy
EP4282969A3 (en) * 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
WO2018183888A2 (en) * 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
CN113811327A (zh) * 2019-03-11 2021-12-17 卢西德生物有限公司 MUC1平行CAR(pCAR)治疗剂
EP4021485A1 (en) * 2019-08-28 2022-07-06 King's College London B cell targeted parallel car (pcar) therapeutic agents
EP4136119A4 (en) * 2020-04-17 2024-09-11 Regeneron Pharmaceuticals, Inc. MODIFIED CCR POLYPEPTIDES AND USES THEREOF

Similar Documents

Publication Publication Date Title
Wu et al. Natural killer cells in cancer biology and therapy
Jia et al. NK cell exhaustion in the tumor microenvironment
Liu et al. TCR-T immunotherapy: the challenges and solutions
Berrien-Elliott et al. Allogeneic natural killer cell therapy
Imani et al. Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy
Shin et al. NK cell-based immunotherapies in cancer
Yilmaz et al. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Merino et al. Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.
Introna CIK as therapeutic agents against tumors
Zhang et al. Treg: a promising immunotherapeutic target in oral diseases
Romee et al. Utilizing cytokines to function‐enable human NK cells for the immunotherapy of cancer
Introna et al. Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms
Pan et al. NK cell-based immunotherapy and therapeutic perspective in gliomas
Duya et al. Nature products of traditional Chinese medicine provide new ideas in γδT cell for tumor immunotherapy
Mortezaee et al. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives
Khalifeh et al. Engineering resilient CAR T cells for immunosuppressive environment
Basher et al. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC
Yu et al. Viral-and tumor-reactive natural killer cells
Oyer et al. PM21-particle stimulation augmented with cytokines enhances NK cell expansion and confers memory-like characteristics with enhanced survival
Deng et al. Prospects and limitations of NK cell adoptive therapy in clinical applications
Van Elssen et al. NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect?
JP5751277B2 (ja) Ｎｋ細胞活性化方法、これを用いたｎｋ細胞増殖方法及び細胞製造方法並びにｎｋ細胞を含む単核球
JPWO2022094314A5 (https=)
Hanagiri et al. Retracted: Antitumor activity of human γδ T cells transducted with CD 8 and with T‐cell receptors of tumor‐specific cytotoxic T lymphocytes
WO2022164959A1 (en) Improved immune cell therapy